These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 32110131)

  • 1. Multiagonist Unimolecular Peptides for Obesity and Type 2 Diabetes: Current Advances and Future Directions.
    Hasib A
    Clin Med Insights Endocrinol Diabetes; 2020; 13():1179551420905844. PubMed ID: 32110131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incretin hormones: Their role in health and disease.
    Nauck MA; Meier JJ
    Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():5-21. PubMed ID: 29364588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.
    Finan B; Ma T; Ottaway N; Müller TD; Habegger KM; Heppner KM; Kirchner H; Holland J; Hembree J; Raver C; Lockie SH; Smiley DL; Gelfanov V; Yang B; Hofmann S; Bruemmer D; Drucker DJ; Pfluger PT; Perez-Tilve D; Gidda J; Vignati L; Zhang L; Hauptman JB; Lau M; Brecheisen M; Uhles S; Riboulet W; Hainaut E; Sebokova E; Conde-Knape K; Konkar A; DiMarchi RD; Tschöp MH
    Sci Transl Med; 2013 Oct; 5(209):209ra151. PubMed ID: 24174327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Incretin-based co- and tri-agonists : Innovative polypharmacology for the treatment of obesity and diabetes].
    Harger A; Stemmer K; Tschöp MH; Müller TD
    Internist (Berl); 2019 Sep; 60(9):895-902. PubMed ID: 31346639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide-based multi-agonists: a new paradigm in metabolic pharmacology.
    Brandt SJ; Müller TD; DiMarchi RD; Tschöp MH; Stemmer K
    J Intern Med; 2018 Dec; 284(6):581-602. PubMed ID: 30230640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion-A Review.
    Mathiesen DS; Bagger JI; Bergmann NC; Lund A; Christensen MB; Vilsbøll T; Knop FK
    Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31443356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
    Skow MA; Bergmann NC; Knop FK
    Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterisation and antidiabetic utility of a novel hybrid peptide, exendin-4/gastrin/xenin-8-Gln.
    Hasib A; Ng MT; Khan D; Gault VA; Flatt PR; Irwin N
    Eur J Pharmacol; 2018 Sep; 834():126-135. PubMed ID: 30025814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects.
    Elahi D; McAloon-Dyke M; Fukagawa NK; Meneilly GS; Sclater AL; Minaker KL; Habener JF; Andersen DK
    Regul Pept; 1994 Apr; 51(1):63-74. PubMed ID: 8036284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gut Peptide Agonism in the Treatment of Obesity and Diabetes.
    Grandl G; Novikoff A; DiMarchi R; Tschöp MH; Müller TD
    Compr Physiol; 2019 Dec; 10(1):99-124. PubMed ID: 31853954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel approaches to anti-obesity drug discovery with gut hormones over the past 10 years.
    Rose F; Bloom S; Tan T
    Expert Opin Drug Discov; 2019 Nov; 14(11):1151-1159. PubMed ID: 31355685
    [No Abstract]   [Full Text] [Related]  

  • 12. Rapid selection of a novel GLP-1/GIP dual receptor agonist with prolonged glycemic control and weight loss in rodent animals.
    Wu Y; Ji T; Lv J; Wang Z
    Life Sci; 2020 Sep; 257():118025. PubMed ID: 32598933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut hormone polyagonists for the treatment of type 2 diabetes.
    Brandt SJ; Götz A; Tschöp MH; Müller TD
    Peptides; 2018 Feb; 100():190-201. PubMed ID: 29412819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastric inhibitory polypeptide analogues: do they have a therapeutic role in diabetes mellitus similar to that of glucagon-like Peptide-1?
    Holst JJ
    BioDrugs; 2002; 16(3):175-81. PubMed ID: 12102645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The entero-insular axis: implications for human metabolism.
    Ranganath LR
    Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GLP-1/glucagon receptor co-agonism for treatment of obesity.
    Sánchez-Garrido MA; Brandt SJ; Clemmensen C; Müller TD; DiMarchi RD; Tschöp MH
    Diabetologia; 2017 Oct; 60(10):1851-1861. PubMed ID: 28733905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes.
    Capozzi ME; DiMarchi RD; Tschöp MH; Finan B; Campbell JE
    Endocr Rev; 2018 Oct; 39(5):719-738. PubMed ID: 29905825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Diabetes and Obesity by Rationally Designed Peptide Agonists Functioning at Multiple Metabolic Receptors.
    Khajavi N; Biebermann H; Tschöp M; DiMarchi R
    Endocr Dev; 2017; 32():165-182. PubMed ID: 28873389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice.
    Jall S; Sachs S; Clemmensen C; Finan B; Neff F; DiMarchi RD; Tschöp MH; Müller TD; Hofmann SM
    Mol Metab; 2017 May; 6(5):440-446. PubMed ID: 28462078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twincretin as a potential therapeutic for the management of type 2 diabetes with obesity.
    Usui R; Yabe D; Seino Y
    J Diabetes Investig; 2019 Jul; 10(4):902-905. PubMed ID: 30637966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.